SGLT2 Inhibitor Shows Promise as MASH Treatment

MedPage Today) — An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found.
In 154 adults with biopsy-diagnosed MASH, improvement without…